80jili ph
80jili ph
The Latest: UnitedHealthcare shooting suspect contests his extradition back to New YorkThe people that president-elect Donald Trump has selected to lead federal health agencies in his second administration include a retired congressman, a surgeon and a former talk-show host. All of them could play pivotal roles in fulfilling a new political agenda that could change how the government goes about safeguarding Americans' health — from health care and medicines to food safety and science research. And if Congress approves, at the helm of the team as Department of Health and Human Services secretary will be prominent environmental lawyer and anti-vaccine organizer Robert F. Kennedy Jr. By and large, the nominees don't have experience running large bureaucratic agencies, but they know how to talk about health on TV . Centers for Medicare and Medicaid pick Dr. Mehmet Oz hosted a talk show for 13 years and is a well-known wellness and lifestyle influencer. The pick for the Food and Drug Administration, Dr. Marty Makary, and for surgeon general, Dr. Janette Nesheiwat, are frequent Fox News contributors. Many on the list were critical of COVID-19 measures like masking and booster vaccinations for young people. Some of them have ties to Florida like many of Trump's other Cabinet nominees: CDC pick Dr. Dave Weldon represented the state in Congress for 14 years and is affiliated with a medical group on the state's Atlantic coast. Nesheiwat's brother-in-law is Rep. Mike Waltz , R-Fla., tapped by Trump as national security adviser. Here's a look at the nominees' potential role in carrying out what Kennedy says is the task to “reorganize” agencies, which have an overall $1.7 billion budget; employ 80,000 scientists, researchers, doctors and other officials; and affect the lives of all Americans. Centers for Disease Control and Prevention The Atlanta-based CDC, with a $9.2 billion core budget, is charged with protecting Americans from disease outbreaks and other public health threats. Kennedy has long attacked vaccines and criticized the CDC, repeatedly alleging corruption at the agency. He said on a 2023 podcast that there is "no vaccine that is safe and effective,” and urged people to resist the CDC's guidelines on if and when kids should get vaccinated . Decades ago, Kennedy found common ground with Weldon , the 71-year-old nominee to run the CDC who served in the Army and worked as an internal medicine doctor before he represented a central Florida congressional district from 1995 to 2009. Starting in the early 2000s, Weldon had a prominent part in a debate about whether there was a relationship between a vaccine preservative called thimerosal and autism. He was a founding member of the Congressional Autism Caucus and tried to ban thimerosal from all vaccines. Kennedy, then a senior attorney for the Natural Resources Defense Council, believed there was a tie between thimerosal and autism and also charged that the government hid documents showing the danger. Since 2001, all vaccines manufactured for the U.S. market and routinely recommended for children 6 years or younger have contained no thimerosal or only trace amounts, with the exception of inactivated influenza vaccine. Meanwhile, study after study after study found no evidence that thimerosal caused autism. Weldon's congressional voting record suggests he may go along with Republican efforts to downsize the CDC, including to eliminate the National Center for Injury Prevention and Control, which works on topics like drownings, drug overdoses and shooting deaths. Weldon also voted to ban federal funding for needle-exchange programs as an approach to reduce overdoses, and the National Rifle Association gave him an “A” rating for his pro-gun rights voting record. Food and Drug Administration Kennedy is extremely critical of the FDA, which has 18,000 employees and is responsible for the safety and effectiveness of prescription drugs, vaccines and other medical products — as well as overseeing cosmetics, electronic cigarettes and most foods. Makary, Trump’s pick to run the FDA, is closely aligned with Kennedy on several topics . The professor at Johns Hopkins University who is a trained surgeon and cancer specialist has decried the overprescribing of drugs, the use of pesticides on foods and the undue influence of pharmaceutical and insurance companies over doctors and government regulators. Kennedy has suggested he'll clear our “entire” FDA departments and also recently threatened to fire FDA employees for “aggressive suppression” of a host of unsubstantiated products and therapies, including stem cells, raw milk , psychedelics and discredited COVID-era treatments like ivermectin and hydroxychloroquine. Makary's contrarian views during the COVID-19 pandemic including the need for masking and giving young kids COVID vaccine boosters. But anything Makary and Kennedy might want to do when it comes to unwinding FDA regulations or revoking long-standing vaccine and drug approvals would be challenging. The agency has lengthy requirements for removing medicines from the market, which are based on federal laws passed by Congress. Centers for Medicaid and Medicare Services The agency provides health care coverage for more than 160 million people through Medicaid, Medicare and the Affordable Care Act, and also sets Medicare payment rates for hospitals, doctors and other providers. With a $1.1 trillion budget and more than 6,000 employees, Oz has a massive agency to run if confirmed — and an agency that Kennedy hasn't talked about much when it comes to his plans. While Trump tried to scrap the Affordable Care Act in his first term, Kennedy has not taken aim at it yet. But he has been critical of Medicaid and Medicare for covering expensive weight-loss drugs — though they're not widely covered by either . Trump said during his campaign that he would protect Medicare, which provides insurance for older Americans. Oz has endorsed expanding Medicare Advantage — a privately run version of Medicare that is popular but also a source of widespread fraud — in an AARP questionnaire during his failed 2022 bid for a U.S. Senate seat in Pennsylvania and in a 2020 Forbes op-ed with a former Kaiser Permanente CEO. Oz also said in a Washington Examiner op-ed with three co-writers that aging healthier and living longer could help fix the U.S. budget deficit because people would work longer and add more to the gross domestic product. Neither Trump nor Kennedy have said much about Medicaid, the insurance program for low-income Americans. Trump's first administration reshaped the program by allowing states to introduce work requirements for recipients. Surgeon general Kennedy doesn't appear to have said much publicly about what he'd like to see from surgeon general position, which is the nation's top doctor and oversees 6,000 U.S. Public Health Service Corps members. The surgeon general has little administrative power, but can be an influential government spokesperson on what counts as a public health danger and what to do about it — suggesting things like warning labels for products and issuing advisories. The current surgeon general, Vivek Murthy, declared gun violence as a public health crisis in June. Trump's pick, Nesheiwat, is employed as a New York City medical director with CityMD, a group of urgent care facilities in the New York and New Jersey area, and has been at City MD for 12 years. She also has appeared on Fox News and other TV shows, authored a book on the “transformative power of prayer” in her medical career and endorses a brand of vitamin supplements. She encouraged COVID-19 vaccines during the pandemic, calling them “a gift from God” in a February 2021 Fox News op-ed, as well as anti-viral pills like Paxlovid. In a 2019 Q&A with the Women in Medicine Legacy Foundation , Nesheiwat said she is a “firm believer in preventive medicine” and “can give a dissertation on hand-washing alone.” National Institutes of Health As of Saturday, Trump had not yet named his choice to lead the National Institutes of Health, which funds medical research through grants to researchers across the nation and conducts its own research. It has a $48 billion budget. Kennedy has said he'd pause drug development and infectious disease research to shift the focus to chronic diseases. He'd like to keep NIH funding from researchers with conflicts of interest, and criticized the agency in 2017 for what he said was not doing enough research into the role of vaccines in autism — an idea that has long been debunked . Associated Press writers Amanda Seitz and Matt Perrone and AP editor Erica Hunzinger contributed to this report. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
921 student awarded degrees at IGDTUW seventh convocation
No. 4-ranked South Dakota stuns top-ranked Bison with last-second touchdownBy Khari A. Thompson The Patriots have a young, promising quarterback in Drake Maye. Since taking over for Jacoby Brissett, Maye has shown flashes of arm strength, athleticism, and poise that should bode well for his future. But, it hasn’t translated to wins. The Patriots (3-10) are still in the mix for a top-5 pick in the upcoming NFL Draft. Bill Simmons, who is the founder and CEO of The Ringer and a longtime Boston sports fan, is less than impressed with the job the Patriots have done surrounding Maye with talent. He shared his frustrations with the way New England handled the offseason on X. “If you take out picking Drake Maye at #3 (which was the most obvious pick possible),” Simmons wrote. “The Patriots first offseason of draft picks and free agent signings without Belichick was legitimately an F-minus. Bad draft picks and super-cheap discount spending. You get what you pay for.” The Patriots, who were in need of a quarterback after a pair of disastrous seasons from Mac Jones, selected Maye No. 3 overall. Caleb Williams and Jayden Daniels were already off the board by then. The Patriots had at least one offer to trade down, but they stood pat and took Maye. If you take out picking Drake Maye at #3 (which was the most obvious pick possible), the Patriots first offseason of draft picks and free agent signings without Belichick was legitimately an F-minus. Bad draft picks and super-cheap discount spending. You get what you pay for. https://t.co/eVzSNZa0qM The other picks in the draft have not added much production this season. Second-round pick Ja’Lynn Polk has 12 catches for 87 yards and a pair of touchdowns in 12 games this season. That’s an average of one catch for 7.25 yards per game. Javon Baker has zero catches on one target in eight games. Tight-end Jaheim Bell has one catch for one yard. Offensive linemen Caedan Wallace and Layden Robinson have combined for eight starts. Marcellas Dial has six tackles and a forced fumble. Joe Milton hasn’t thrown a pass since the preseason. Simmons’s post was a reaction to a report about the Patriots’ decision to waive receiver KJ Osborn. Osborn, who posted 48 catches for 540 yards and three touchdowns last season with Minnesota, saw his production dip dramatically after signing with the Patriots in the offseason. He fell out of the Patriots’ rotation, catching seven passes for 57 yards and one touchdown in seven games. Despite signing Christian Barmore, Kyle Dugger, Rhamondre Stevenson, Jabrill Peppers, and Mike Onwenu among others to contract extensions, the Patriots ended up with more than $35 million in leftover cap space, which is third-most in the league according to Spotrac. They brought in Antonio Gibson, who was a former 1,000-yard rusher with the Commanders. He has 373 yards and one touchdown in 13 games. They signed Chukwuma Okorafor, whom they hoped would be part of the solution at left tackle. He left the team. Defensive back Jaylinn Hawkins, who has 39 tackles, has been one of the more productive offseason acquisitions. The Patriots are four games away from their second offseason under Eliot Wolf and Jerod Mayo. The roster has many holes left to fill. Khari A. Thompson Khari Thompson covers professional sports for Boston.com. Before joining the team in 2022, Khari covered college football for The Clarion Ledger in Jackson, Miss. Sign up for Patriots updates🏈 Get breaking news and analysis delivered to your inbox during football season. Be civil. Be kind.
Dec. 24—Dick Hoak, whose playing and coaching career with the Steelers spanned 45 years, is among three former assistant coaches who have been selected for the Awards of Excellence program by the Pro Football Hall of Fame. Hoak, a Jeannette native who played at Penn State, played 10 seasons with the Steelers before he was hired by Chuck Noll in 1972 to be the team's running backs coach. He was the only assistant from Noll's staff who was retained when Bill Cowher took over as head coach in 1992. All told, Hoak was involved in 742 games with the Steelers as a player and coach. He is a member of the team's Hall of Honor. Hoak was a seventh-round draft choice in 1971 who rushed for 1,132 yards and 25 touchdowns and caught 146 passes for 1,452 yards and eight touchdowns in his career. He was the team's second all-time leading rusher when he retired after the 1970 season. In addition to Hoak, Elijah Pitts of the Buffalo Bills and Jim McNally of the Cincinnati Bengals were the other assistant coaches selected for the Awards of Excellence program. They will be honored in Canton, Ohio, during an awards ceremony June 25-26. (c)2024 the Pittsburgh Post-Gazette Visit the Pittsburgh Post-Gazette at www.post-gazette.com Distributed by Tribune Content Agency, LLC.LAHAINA, Hawaii (AP) — Tyrese Hunter scored 17 of his 26 points after halftime to lead Memphis to a 99-97 overtime win against two-time defending national champion and second-ranked UConn on Monday in the first round of the Maui Invitational . Hunter shot 7 of 10 from 3-point range for the Tigers (5-0), who were 12 of 22 from beyond at the arc as a team. PJ Haggerty had 22 points and five assists, Colby Rogers had 19 points and Dain Dainja scored 14. Tarris Reed Jr. had 22 points and 11 rebounds off the bench for the Huskies (4-1). Alex Karaban had 19 points and six assists, and Jaylin Stewart scored 16. Memphis led by as many as 13 with about four minutes left in regulation, but UConn chipped away and eventually tied it on Solo Ball’s 3-pointer with 1.2 seconds remaining. Memphis: The Tigers ranked second nationally in field goal percentage going into the game and shot it at a 54.7% clip. UConn: The Huskies saw their string of 17 consecutive wins dating back to February come to an end. The teams were tied at 92 with less than a minute remaining in overtime when UConn coach Dan Hurley was assessed a technical foul for his displeasure with an over-the-back call against Liam McNeeley. PJ Carter hit four straight free throws — two for the tech and the other pair for the personal foul — to give Memphis a 96-92 lead with 40.3 seconds to play. UConn had three players foul out. Memphis attempted 40 free throws and made 29 of them. Memphis will play the winner of Colorado-Michigan State on Tuesday in the second round of the invitational. UConn will play the loser of that game in the consolation bracket. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball .LAS VEGAS — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. "As the pinnacle of motorsports, F1 demands boundary-pushing innovation and excellence. It's an honor for General Motors and Cadillac to join the world's premier racing series, and we're committed to competing with passion and integrity to elevate the sport for race fans around the world," GM President Mark Reuss said. "This is a global stage for us to demonstrate GM's engineering expertise and technology leadership at an entirely new level." The approval ends years of wrangling that launched a U.S. Justice Department investigation into why Colorado-based Liberty Media, the commercial rights holder of F1, would not approve the team initially started by Michael Andretti. Andretti in September stepped aside from leading his namesake organization, so the 11th team will be called Cadillac F1 and be run by new Andretti Global majority owners Dan Towriss and Mark Walter. The team will use Ferrari engines its first two years until GM has a Cadillac engine built for competition in time for the 2028 season. Towriss is the the CEO and president of Group 1001 and entered motorsports via Andretti's IndyCar team when he signed on financial savings platform Gainbridge as a sponsor. Towriss is now a major part of the motorsports scene with ownership stakes in both Spire Motorsports' NASCAR team and Wayne Taylor Racing's sports car team. Walter is the chief executive of financial services firm Guggenheim Partners and the controlling owner of both the World Series champion Los Angeles Dodgers and Premier League club Chelsea. "We're excited to partner with General Motors in bringing a dynamic presence to Formula 1," Towriss said. "Together, we're assembling a world-class team that will embody American innovation and deliver unforgettable moments to race fans around the world." Mario Andretti, the 1978 F1 world champion, will have an ambassador role with Cadillac F1. But his son, Michael, will have no official position with the organization now that he has scaled back his involvement with Andretti Global. "The Cadillac F1 Team is made up of a strong group of people that have worked tirelessly to build an American works team," Michael Andretti posted on social media. "I'm very proud of the hard work they have put in and congratulate all involved on this momentous next step. I will be cheering for you!" The approval has been in works for weeks but was held until after last weekend's Las Vegas Grand Prix to not overshadow the showcase event of the Liberty Media portfolio. Max Verstappen won his fourth consecutive championship in Saturday night's race, the third and final stop in the United States for the top motorsports series in the world. Grid expansion in F1 is both infrequent and often unsuccessful. Four teams were granted entries in 2010 that should have pushed the grid to 13 teams and 26 cars for the first time since 1995. One team never made it to the grid and the other three had vanished by 2017. There is only one American team on the current F1 grid — owned by California businessman Gene Haas — but it is not particularly competitive and does not field American drivers. Andretti's dream was to field a truly American team with American drivers. The fight to add this team has been going on for three-plus years, and F1 initially denied the application despite approval from F1 sanctioning body FIA. The existing 10 teams, who have no voice in the matter, also largely opposed expansion because of the dilution in prize money and the billions of dollars they've already invested in the series. Andretti in 2020 tried and failed to buy the existing Sauber team. From there, he applied for grid expansion and partnered with GM, the top-selling manufacturer in the United States. The inclusion of GM was championed by the FIA and president Mohammed Ben Sulayem, who said Michael Andretti's application was the only one of seven applicants to meet all required criteria to expand F1's current grid. "General Motors is a huge global brand and powerhouse in the OEM world and is working with impressive partners," Ben Sulayem said Monday. "I am fully supportive of the efforts made by the FIA, Formula 1, GM and the team to maintain dialogue and work towards this outcome of an agreement in principle to progress this application." Despite the FIA's acceptance of Andretti and General Motors from the start, F1 wasn't interested in Andretti — but did want GM. At one point, F1 asked GM to find another team to partner with besides Andretti. GM refused and F1 said it would revisit the Andretti application if and when Cadillac had an engine ready to compete. "Formula 1 has maintained a dialogue with General Motors, and its partners at TWG Global, regarding the viability of an entry following the commercial assessment and decision made by Formula 1 in January 2024," F1 said in a statement. "Over the course of this year, they have achieved operational milestones and made clear their commitment to brand the 11th team GM/Cadillac, and that GM will enter as an engine supplier at a later time. Formula 1 is therefore pleased to move forward with this application process." Yet another major shift in the debate over grid expansion occurred earlier this month with the announced resignation of Liberty Media CEO Greg Maffei, who was largely believed to be one of the biggest opponents of the Andretti entry. "With Formula 1's continued growth plans in the US, we have always believed that welcoming an impressive US brand like GM/Cadillac to the grid and GM as a future power unit supplier could bring additional value and interest to the sport," Maffei said. "We credit the leadership of General Motors and their partners with significant progress in their readiness to enter Formula 1." Get local news delivered to your inbox!
Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic modalities to target cancers. Due to recent communications with the U.S. Food and Drug Administration (FDA, or the Agency) regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the Company has decided to pursue strategic options for the further development and commercialization of this product candidate. The CLOVER-WaM study was conducted in accordance with earlier FDA communications from an end of Phase 2 meeting and from a meeting in early 2024, during which the Company was informed that positive results for major response rate (MRR) as the primary endpoint could be acceptable to support accelerated approval of iopofosine I 131 as a treatment for Waldenstrom’s macroglobulinemia (WM). Based upon a recent Type-C meeting with the FDA, the Company now believes that a submission seeking accelerated approval would need to be based on the MRR data from CLOVER-WaM and enrollment in a randomized, controlled confirmatory study that is designed to generate data on progression-free survival (PFS). “While iopofosine I 131’s positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources. Importantly, partnering or divesting this program supports our commitment to providing this potentially life-saving drug to the patients who need it as quickly as possible,” stated James Caruso, president and CEO of Cellectar. “We believe iopofosine I 131 represents a compelling opportunity as it has shown strong efficacy and good tolerability based on our clinical studies. Moreover, the commercial work we conducted demonstrates iopofosine I 131’s substantial market opportunity based upon the product profile, which includes off-the-shelf global distribution, orphan pricing and existing unmet medical need.” Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131’s clinical success validates the platform’s ability to target cancers and Cellectar will leverage its experience to focus on the development of its earlier clinical programs. Specifically, Cellectar will focus on those assets it believes have the highest therapeutic potential and opportunity for value creation. As highlighted by recent acquisitions and collaborations within the radiopharmaceutical sector, precision isotopes like alpha- and Auger-emitters have emerged as the leading therapeutics of interest. Consequently, the Company will now focus its resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. Cellectar expects to file Investigational New Drug applications in the first half of 2025 for both CLR-121225 and CLR-121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers. Both programs have demonstrated robust in vivo activity, tolerability, excellent targeting and uptake in preclinical solid tumor models. The Company believes this approach will provide an expedited timeframe to achieve safety and proof-of-concept data in patients. The Company’s strategic reprioritization will impact all departments and result in an immediate reduction in headcount of approximately 60%, which should be complete by the end of the fourth quarter 2024. The Company anticipates that the implementation of the restructuring will extend its cash runway into the third quarter of 2025. “We are being methodical in our efforts to reorganize the company with the goal of conserving cash while maintaining the flexibility to execute immediate priorities and build for long-term growth and value creation. This reorganization is difficult but necessary for the future growth potential of Cellectar,” said Mr. Caruso. “I want to extend my deepest gratitude to our departing employees for their significant contributions to our work and their dedication to making a difference in the lives of patients.” About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset, iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer, CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 is under evaluation in Phase 2b studies for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, alongside the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 Orphan Drug and Fast Track Designations for various cancer indications. New data from the CLOVER-WaM Phase 2 clinical trial were recently presented in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024). For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook. Forward-Looking Statement Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to obtain regulatory exclusivities, the availability of priority review vouchers, our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. Contacts MEDIA: Christy Maginn Bliss Bio Health 703-297-7194 cmaginn@blissbiohealth.com INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 annemarie.fields@precisionaq.com
Vikings right guard Dalton Risner says he’ll continue to get better at new positionF1 expands grid, adds Cadillac brand and new American team for '26Natixis Advisors LLC lifted its holdings in shares of Infosys Limited ( NYSE:INFY – Free Report ) by 63.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 266,942 shares of the technology company’s stock after acquiring an additional 103,659 shares during the period. Natixis Advisors LLC’s holdings in Infosys were worth $5,945,000 as of its most recent filing with the SEC. Several other institutional investors have also made changes to their positions in INFY. Mizuho Securities Co. Ltd. bought a new position in Infosys during the third quarter worth about $33,000. GAMMA Investing LLC boosted its stake in Infosys by 22.6% in the 2nd quarter. GAMMA Investing LLC now owns 2,931 shares of the technology company’s stock valued at $55,000 after buying an additional 541 shares in the last quarter. Hilltop National Bank grew its position in Infosys by 50.8% in the second quarter. Hilltop National Bank now owns 2,979 shares of the technology company’s stock valued at $55,000 after acquiring an additional 1,004 shares during the period. Whittier Trust Co. of Nevada Inc. raised its stake in Infosys by 126.7% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 3,029 shares of the technology company’s stock worth $56,000 after acquiring an additional 1,693 shares in the last quarter. Finally, Ridgewood Investments LLC bought a new position in shares of Infosys during the second quarter valued at $162,000. 10.89% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth Several equities research analysts have recently weighed in on the stock. Investec lowered shares of Infosys from a “hold” rating to a “sell” rating in a report on Thursday, October 3rd. Erste Group Bank raised shares of Infosys from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. StockNews.com downgraded Infosys from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, BMO Capital Markets raised their price target on Infosys from $23.00 to $25.00 and gave the company a “market perform” rating in a report on Friday, October 18th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.85. Infosys Stock Performance Shares of INFY stock opened at $22.80 on Friday. The firm’s 50 day moving average price is $22.24 and its two-hundred day moving average price is $20.74. The stock has a market cap of $94.43 billion, a PE ratio of 29.23, a PEG ratio of 3.51 and a beta of 1.00. Infosys Limited has a 52-week low of $16.04 and a 52-week high of $23.48. Infosys ( NYSE:INFY – Get Free Report ) last announced its quarterly earnings data on Thursday, October 17th. The technology company reported $0.19 EPS for the quarter, hitting analysts’ consensus estimates of $0.19. Infosys had a return on equity of 31.43% and a net margin of 17.15%. The business had revenue of $4.89 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the firm earned $0.18 earnings per share. As a group, sell-side analysts predict that Infosys Limited will post 0.75 earnings per share for the current fiscal year. Infosys Increases Dividend The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, October 29th. Stockholders of record on Friday, January 1st were paid a dividend of $0.2126 per share. The ex-dividend date of this dividend was Tuesday, October 29th. This represents a dividend yield of 1.1%. This is a boost from Infosys’s previous semi-annual dividend of $0.20. Infosys’s dividend payout ratio is currently 53.85%. Infosys Company Profile ( Free Report ) Infosys Limited, together with its subsidiaries, provides consulting, technology, outsourcing, and next-generation digital services in North America, Europe, India, and internationally. It provides digital marketing and digital workplace, digital commerce, digital experience and interactions, metaverse, data analytics and AI, applied AI, generative AI, sustainability, blockchain, engineering, Internet of Things, enterprise agile DevOps, application modernization, cloud, digital process automation, digital supply chain, Microsoft business application and cloud business, service experience transformation, energy transition, cyber security, and quality engineering solutions; Oracle, SAP, and Saleforce solutions; API economy and microservices; and Topaz, an AI-first set of services, solutions, and platforms using generative AI technologies. Recommended Stories Want to see what other hedge funds are holding INFY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Infosys Limited ( NYSE:INFY – Free Report ). Receive News & Ratings for Infosys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infosys and related companies with MarketBeat.com's FREE daily email newsletter .
Step Aside, Jaguar: Different Car Company Puts Them to Shame with Pro-Family AdJoe Burrow's home broken into during Monday Night Football in latest pro-athlete home invasion
None
Ifedi starts at left tackle for Browns in prime-time matchup against AFC North-leading SteelersHealth minister Lesa Semmler said the NWT Health and Social Services Leadership Council will be dissolved on December 16. Public administrator Dan Florizone, a former healthcare leader in Saskatchewan and Nunavut, will take over. In a statement, the N.W.T. government said the territory’s health authority needed “enhanced strategic direction.” The leadership council – formed in 2016 – acted in a similar fashion to a board of governors, overseeing the work of the staff who actually manage the health authority on a day-to-day basis. The council’s current chair is Gerry Cheezie, a former Smith’s Landing First Nation chief who was appointed in 2022. Cheezie said he would provide comment later on Tuesday. Another of the council’s eight present members, reached by phone on Tuesday afternoon, said they were not authorized to speak about the GNWT’s decision but told Cabin Radio they supported the decision. “The role and structure of the leadership council as the board of management of the NTHSSA has not proven to fit the rapidly evolving and challenging needs of the current health and social services system, nor within the broader context of the GNWT,” the territorial government said in a statement “The goal in appointing a public administrator is to enable a more nimble approach and support efforts to find and implement solutions.” The GNWT said Florizone “has experience leading large-scale change across the Saskatchewan health sector, the Saskatchewan education sector, and throughout the Government of Saskatchewan.” He will be “responsible for exercising all powers and performing all duties and functions of the leadership council,” the GNWT added. Regional wellness councils, whose chairs formed the overall leadership council, will continue. The GNWT said appointing a public administrator was “not unprecedented.” Hay River’s health authority has one, the territory said – Brian Willows, who also sat on the leadership council in that role. The Tłıchǫ Community Services Agency, which is the N.W.T. health authority’s equivalent for Tłıchǫ communities, will continue to be governed by a board. “This decision was not made without significant consideration and deliberation and does not reflect any failings on the part of the leadership council or the NTHSSA,” Semmler was quoted as saying. “Appointing a public administrator provides the dedicated, full-time leadership needed to tackle the significant challenges in our health and social services system and deliver real, lasting improvements for all northerners “This is an important step toward fostering healthy people and communities across the territory. By establishing strong, focused leadership, we aim to address longstanding challenges within the system and lay a more resilient foundation for the future.” The health authority’s chief executive and its current management team, who sit below board level and will answer to the new public administrator, remain unchanged. In a Q&A published alongside its news release, the territorial government said the change “reflects a current need for specific expertise in managing the needs of the NTHSSA under increasing pressures and operational and financial challenges the system is currently facing.” The territory said it had considered candidates in the NWT to become the public administrator, but “could not identify a candidate who met the requirements and was willing to take on the role.” “Mr Florizone brings the expertise required, the time and capacity to take this on,” the GNWT said, “and the experience working in a northern context.” More follows. Aastha Sethi contributed reporting.
